June 13-16, 2022
San Diego, CA
FUJIFILM Diosynth Biotechnologies is delighted to attend BIO 2022, June 13th-16th, San Diego, CA. Stop by booth 1427 in the BioProcess Zone, book a meeting with our team by searching FUJIFILM Diosynth Biotechnologies in one-to-one partnering. Learn more about FUJIFILM Diosynth Biotechnologies’ capabilities and how we can help you advance and deliver tomorrow’s medicines.
Meet Our Experts
Monday, June 13, 2022 at 1:55pm
BioProcess Theater Booth 919
Executive Interview with Martin Meeson, Chief Executive Officer, FUJIFILM Diosynth Biotechnologies
Monday, June 13, 2022 at 5pm- 6:30pm
In-Booth Welcome Reception at Booth 1427
Tuesday, June 14, 2022 at 6am-10:25am
EndPoints at the Marrriott Marquis San Diego Marina
Martin Meeson, Chief Executive Officer, FUJIFILM Diosynth Biotechnologies will be providing the opening remarks during the editorial panel session Managing a Biotech in Turbulent Times
Click here to register
Wednesday, June 15, 2022 at 12:15pm
BIO 2022 Super Session sponsored by Fujifilm Life Sciences, San Diego Convention Center Upper Level Session Room 6B
Daniel DeVido, PhD., Senior Director, Strategic Business Development, FUJIFILM Diosynth Biotechnologies is moderating a panel discussion Gut Check: Current Trends in Microbiome Therapeutics Development
As of March 31, 2022, clinicaltrials.gov reports 1,485 ongoing clinical studies related to the microbiome and targeting a myriad of disease indications, including autoimmune, gastrointestinal, infectious, metabolic and oncological disorders. The therapeutic area’s dramatic rise in clinical trial activity and positive results in 2021 illustrates the continuing progress and maturation of the field. With numerous mid-to-late-stage trials well underway, a host of 2022 readouts, and the first-ever microbiome therapy approval potentially on the cards, interest from big pharma and investors continues to grow and indicates that 2022 will be an explosive year for the microbiome field. Join this panel of industry experts as they share recent gains in harnessing the power of the microbiome and what key stakeholders should be watching in the 2H of 2022 and beyond.
Wednesday, June 15, 2022 at 12:45pm
BioProcess Theater Booth 919
Charles Heise, Senior Staff Scientist in the Bioprocessing Strategy & Development group at FUJIFILM Diosynth Biotechnologies is presenting on SymphonX™: Advancing biomanufacturing capabilities with a next generation single use technology solution
The in-house developed downstream purification system SymphonX™ uses a disposable, generic flow path to operate multiple downstream process unit operations (e.g. Chromatography, Tangential Flow Filtration (TFF), Single-Pass TFF, Viral Inactivation and Viral Filtration). This presentation outlines the functional flexibility of the system, its advanced buffer management capabilities (in-line conditioning and in-line dilution) and operational capability improvements. The SymphonX™ design simplifies the single-use consumable supply chain, allows plug and play flexibility across all downstream unit operations and provides a generic operator interface to de-risk execution of complex batch and continuous bioprocessing operations in a multi-product facility.